📬 GYN Oncology Intelligence Digest — Week 2026-W34

BI-1808 plus pembrolizumab wins FDA Fast Track in platinum-resistant ovarian cancer with a 24% confirmed ORR, selinexor maintenance misses PFS in TP53 wild-type endometrial cancer, and FIGO 2023 endometrial staging is challenged on complexity and unproven superiority.

⚡ TL;DR

🐦 Twitter / 🦋 Bluesky

AMH as a marker of chemotherapy benefit: cytotoxicity or ovarian suppression? — AMH may indicate who benefited from chemotherapy but not whether the mechanism is direct cytotoxicity or ovarian suppression
GLP-1 receptor agonist users show a lower endometrial cancer hazard in a real-world obesity cohort — In obese adults without diabetes, obesity-associated cancer occurred in 0.54% vs 0.90%, HR 0.59, with endometrial cancer among the strongest signals at HR 0.42
FDA Fast Track for BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer, on a 24% confirmed response rate — The FDA granted Fast Track designation to BI 1808 plus pembrolizumab for patients with advanced ovarian cancer

Full details below ↓

📄 What's Being Published

Manuscripts:

Persistent low-level real human chorionic gonadotropin after gestational trophoblastic disease: Natural history and predictors of subsequent gestational trophoblastic neoplasia. — Alevato Raphael et al., Gynecol Oncol

Among 7304 patients with GTD, 72 (0.9%) developed persistent low-level real hCG. Spontaneous normalization occurred in 88.4% (38/43) during postmolar surveillance and 75.9% (22/29) after GTN remission. During postmolar surveillance, vaginal hemorrhage (RD: 35.7%, 95% CI: 10.6–60.8), preevacuation hCG ≥100,000 IU/L (RD: 22.7%, 95% CI: 5.2–40.2), and delayed onset of persistent low-level real hCG ≥7 weeks (RD: 16.6%, 95% CI: 3.3–30.0) were associated with increased risk of postmolar GTN; after GTN remission, delayed onset ≥14 weeks carried an RD of 43.8% (95% CI: 19.4–68.1) for relapsed GTN.

Clinical bottom line: Persistent low-level real hCG after gestational trophoblastic disease usually resolves on its own, so surveillance until FIGO criteria are met — not immediate chemotherapy — is the right default, with hemorrhage, high preevacuation hCG, and delayed onset flagging the patients who will need treatment.

Read full article →

The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations. — Repetto Matteo et al., Clin Cancer Res

This study analyzed 68,920 tumor-normal paired samples sequenced with MSK-IMPACT between 2015 and 2023. SMARCA4 alterations were most frequent in thymic epithelial tumors (10.7%), NSCLC (7.1%), bladder cancer (5.6%), and cervical cancer (5%), with class 1 and class 2 alterations occurring in 2.9% and 0.7% of tumors, respectively. In a phase I trial of the BRM degrader PRT3789, patients with monoallelic class 2 SMARCA4 alterations and preserved BRG1 expression saw clinical benefit, including one complete response.

Clinical bottom line: Reporting a SMARCA4 alteration is not enough — cervical cancer carries these alterations in 5% of cases, and allelic status plus functional mutation class should drive who is selected for BRM-targeted agents such as PRT3789.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

AMH as a marker of chemotherapy benefit: cytotoxicity or ovarian suppression?

AMH may indicate who benefited from chemotherapy, but not whether the mechanism is direct cytotoxicity or ovarian suppression — a distinction that matters when interpreting biomarker-stratified outcomes. Until optimal ovarian function suppression plus endocrine therapy is directly compared with chemotherapy, the role of chemotherapy remains debatable. Separately, clinicians noted that Lynch syndrome surveillance should be gene-specific, not one-size-fits-all, and should balance cancer risk with fertility goals. The core question is whether any biomarker of ovarian reserve can settle the mechanism debate short of a head-to-head trial against ovarian function suppression plus endocrine therapy.

Discussed by: @Dr_ElvinaA, @drnutansahu

→ View representative tweet

GLP-1 receptor agonist users show a lower endometrial cancer hazard in a real-world obesity cohort

In obese adults without diabetes, obesity-associated cancer occurred in 0.54% vs 0.90% (HR 0.59), with endometrial cancer among the strongest signals at HR 0.42 — alongside multiple myeloma (HR 0.37), pancreatic cancer (HR 0.40), and colorectal cancer (HR 0.49). Median follow-up was only approximately 2 years, and the study was observational rather than randomized, limiting causal inference. Oncologists also noted that an oral anticoagulation quality improvement program successfully decreased VTE events during first-line chemotherapy for ovarian cancer. The unresolved question is what trial design would be required before GLP-1 agents are discussed as risk-reduction tools in obese patients, given an endometrial cancer HR of 0.42 from two years of observational follow-up.

Discussed by: @ChandrakanthMv, @womenofteal

→ View representative tweet

FDA Fast Track for BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer, on a 24% confirmed response rate

The FDA granted Fast Track designation to BI-1808, an anti-TNFR2 agent, in combination with pembrolizumab for patients with advanced ovarian cancer, based on interim phase 2a data in which the chemotherapy-free combination produced a 24% confirmed ORR in pretreated platinum-resistant ovarian cancer. The designation rests on responses seen in heavily pretreated patients with platinum-resistant disease, without the addition of chemotherapy. Clinicians are weighing whether a 24% confirmed response rate from interim phase 2a data is sufficient to position TNFR2 blockade combined with pembrolizumab as a serious contender in this setting.

Discussed by: @CancerNetwrk, @TargetedOnc, @SJA_McC, @OncLive, @Larvol

→ View representative tweet

🔥 Top Ranked Tweets

Journal of Clinical Oncology @JCO_ASCO

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0

Read the full article. https://t.co/HakOT4v7QQ
#gyncsm

🔖 3 ❤️ 6 🔁 3 👁 2,062